Epidermolysis Bullosa Global Clinical Trials Review, H1, 2016

GlobalData's clinical trial report, "Epidermolysis Bullosa Global Clinical Trials Review, H1, 2016" provides an overview of Epidermolysis Bullosa clinical trials scenario. This report provides top line data relating to the clinical trials on Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months.

Reasons to buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level.

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Clinical Trials by G7 Countries: Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Sponsors 21
Top Companies Participating in Epidermolysis Bullosa Therapeutics Clinical Trials 22
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 54
Abbreviations 54
Definitions 54
Research Methodology 55
Secondary Research 55
About GlobalData 56
Contact Us 56
Disclaimer 56
Source 57

List of Tables

Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region, 2016* 5
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2016* 12
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase, 2016* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2016* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 20
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24

List of Figures

Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2016* 12
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase (%), 2016* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2016* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 20
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 22
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24
GlobalData Methodology 55